AI Issuer Brief
Arphra AILoading cached brief…
Peers
- TEVATeva Pharmaceutical Industries Limited$34.95$40.7B
- UTHRUnited Therapeutics Corporation$570.40$25B
- DXCMDexCom, Inc.$61.35$23.67B
- DGXQuest Diagnostics Incorporated$192.67$21.33B
- LHLabcorp Holdings Inc.$255.84$21.06B
- STESTERIS plc$214.40$21.04B
- INCYIncyte Corporation$96.91$19.36B
- WATWaters Corporation$307.12$18.28B
Price change · trailing returns
Live · FMP| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.20% | +0.87% | +3.55% | +2.18% | +7.64% | +11.37% | +49.46% | -33.88% | -26.63% | -32.35% | +6172.00% |
Aftermarket
Live · FMPLast trade
$195.23
1 sh
Bid
$186.03
10 sh
Ask
$200.08
1 sh
Spread
$14.050
Fair value
Football field →Weighted blend
$715.61
+265.10% vs spot
Recommendation
Strong Buy
15 of 16 methods
Method spread
11bull3bear
±5% threshold
Analyst PT consensus: $211.42 (+7.87%)
Total assets
$29.44B
Total debt
$6.95B
Cash & equiv
$3.01B
Operating CF
$2.2B
Free cash flow
$2.05B
Buybacks
$0
Analyst view
DB · price_targets + analyst_gradesConsensus target
$211.42
+7.87% upside
Low
$143.00
Median
$214.00
High
$260.00
Recent actions
0 ↑0 ↓8 hold
- May 01, 2026
- Apr 01, 2026
- Mar 01, 2026
- Feb 01, 2026
- Jan 01, 2026
News
DB · news_items- Update on FDA Priority Review of LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection as a Starting Dose for Early Alzheimer's Diseaseprnewswire.com·May 08, 2026
- Update on FDA Priority Review of LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection as a Starting Dose for Early Alzheimer's Diseaseprnewswire.com·May 08, 2026
Recent quarters
All financials →| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q1 Mar 2026 | $2.48B | $319.5M | $2.15 |
| Q4 Dec 2025 | $2.28B | -$48.41M | $-0.33 |
| Q3 Sep 2025 | $2.45B | $466.5M | $3.17 |
| Q2 Jun 2025 | $2.65B | $634.8M | $4.35 |
| Q1 Mar 2025 | $2.43B | $240.5M | $1.64 |
| Q4 Dec 2024 | $2.45B | $266.7M | $1.83 |
Recent insiders
All →| Insider | Action | Shares | Value | Date |
|---|---|---|---|---|
Murphy Nicole officer: Head of Pharm Ops and Tech | Buy | 3 | $585.11 | Feb 12, 2026 |
Singhal Priya officer: Head of Development | Sell | 2,660 | $531.55K | Feb 09, 2026 |
Singhal Priya officer: Head of Development | Sell | 748 | $134.12K | Feb 02, 2026 |
Singhal Priya officer: Head of Development | Sell | 517 | $69.05K | Sep 02, 2025 |
Izzar Rachid officer: Head of Global Product Strat. | Sell | 2,223 | $300.11K | Jul 08, 2025 |
Singhal Priya officer: Head of Development | Sell | 3,806 | $480.51K | May 19, 2025 |
Income statement · annual
5y| Period | Revenue | Op income | Net income | EPS | Net margin |
|---|---|---|---|---|---|
| FY 2025 | $9.81B | $1.88B | $1.29B | $8.83 | +13.18% |
| FY 2024 | $9.68B | $2.49B | $1.63B | $11.19 | +16.87% |
| FY 2023 | $9.84B | $2.1B | $1.16B | $7.97 | +11.81% |
| FY 2022 | $10.17B | $2.89B | $3.05B | $20.87 | +29.95% |
| FY 2021 | $10.98B | $2.79B | $1.56B | $10.40 | +14.17% |